AI Summary & Key Takeaways
AI InsightThe following variables wereassessed: age, family history of cancer, smoking status, age of menarche, parity, age at first delivery, related symptoms, clinical staging, histologictype, treatment received, disease-free period, and the time and site of recurrence, as well as treatment of the latter and overall survival.Results: Ten patients were diagnosed as having leiomyosarcoma, a further 10 patients had malignant mixed mullerian tumors, and five hadendometrial stromal sarcoma; the remaining nine patients had other tumors.
📌 3 Key Takeaways
Abstract
Objective: To determine the clinical and pathologic characteristics, prognostic factors, surgical practice, adjuvant therapies, and survivaloutcomes of patients with uterine sarcoma diagnosed and treated in our institution.Material and Methods: Patients diagnosed and treated for uterine sarcomas at our institution from 2009 to 2017 were retrospectively evaluated.All histologic slides from the specimens underwent a thorough pathologic review by a gynecologic pathologist. The following variables wereassessed: age, family history of cancer, smoking status, age of menarche, parity, age at first delivery, related symptoms, clinical staging, histologictype, treatment received, disease-free period, and the time and site of recurrence, as well as treatment of the latter and overall survival.Results: Ten patients were diagnosed as having leiomyosarcoma, a further 10 patients had malignant mixed mullerian tumors, and five hadendometrial stromal sarcoma; the remaining nine patients had other tumors. At the end of our study, 12 (35.3%) patients were alive and inremission, four (11.8%) were alive with disease, 10 (29.4%) were lost to follow-up, and eight (23.5%) had died. The mean survival time was 80.92months, and the 2-year survival rate was 75.6%. We found that survival was significantly shorter in the presence of lymph node involvement,residual tumor, and recurrence.Conclusion: This study serves to inform physicians about the outcome of various uterine sarcomas that were diagnosed and managed at ourcenter. We found that 35.3% of our patients were alive and in remission, 11.8% were alive with disease, 29.4% were lost to follow-up, and 23.5%of patients died. (J Turk Ger Gynecol Assoc 2019; 20: 154-64)